The stock of Insys Therapeutics Inc (NASDAQ:INSY) hit a new 52-week low and has $10.75 target or 6.00% below today’s $11.44 share price. The 9 months bearish chart indicates high risk for the $796.24M company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $10.75 price target is reached, the company will be worth $47.77M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 199,264 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 25.81% since March 10, 2016 and is downtrending. It has underperformed by 33.33% the S&P500.
Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on November, 3. INSY’s profit will be $4.18 million for 47.67 P/E if the $0.06 EPS becomes a reality. After $0.06 actual earnings per share reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $30 is the highest target while $17 is the lowest. The $24 average target is 109.79% above today’s ($11.44) stock price. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, October 10 by Jefferies. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, September 22 report. Jefferies maintained it with “Buy” rating and $23 target price in Wednesday, February 24 report. The stock has “Buy” rating given by Janney Capital on Thursday, April 14. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Jefferies on Thursday, August 4. As per Tuesday, August 4, the company rating was maintained by Oppenheimer. The firm has “Buy” rating by Jefferies given on Tuesday, April 12. As per Friday, August 14, the company rating was downgraded by Zacks.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio fall, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Cypress Funds Limited Liability accumulated 0.41% or 135,584 shares. Gam Ag, a Switzerland-based fund reported 83,940 shares. Moreover, Mizuho Usa has 0.02% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 9,000 shares. Moreover, Next Gru has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 180 shares. Convergence Inv Prtnrs accumulated 0.03% or 15,965 shares. Schroder Invest Mgmt has 0% invested in the company for 72,697 shares. Bridgeway Cap Mgmt accumulated 0% or 13,000 shares. Blackrock Gru Ltd accumulated 0% or 93,015 shares. California Public Employees Retirement Sys, a California-based fund reported 88,600 shares. The Maryland-based Price T Rowe Assoc Inc Md has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Legal & General Group Inc Public Ltd Company holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 6,247 shares. Millennium Management Llc has invested 0.01% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Victory Cap Mngmt holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 3,313 shares. Tci Wealth has 0.03% invested in the company for 3,545 shares. Eqis Cap Management holds 0.08% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 94,774 shares.
Insider Transactions: Since May 11, 2016, the stock had 2 buys, and 4 insider sales for $170,592 net activity. FOURTEAU PATRICK sold $276,900 worth of stock. BRENNAN DANIEL sold $110,752 worth of stock or 5,781 shares. 50,000 shares with value of $641,827 were bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 on Wednesday, May 11. $270,300 worth of Insys Therapeutics Inc (NASDAQ:INSY) shares were sold by STANLEY THEODORE H.
More news for Insys Therapeutics Inc (NASDAQ:INSY) were recently published by: Businessinsider.com, which released: “A pharmaceutical company is fighting marijuana legalization because it would …” on September 13, 2016. Globenewswire.com‘s article titled: “Insys Therapeutics Announces CEO Succession Plan” and published on September 21, 2016 is yet another important article.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.